French National Database of Rare Dermatological Cancers (CARADERM)

May 20, 2026 updated by: University Hospital, Lille

French National Database of Rare Dermatological Cancers: Merkel Cell Carcinoma, Inoperable or Metastatic Basal Cell Carcinoma, Cutaneous Adnexal Carcinomas

Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes.

CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are :

  • to provide epidemiological, clinical and socio-economic characteristics of patients
  • to identify new clinical or epidemiological prognostic factors for these rare cancers
  • to evaluate the impact of various treatments on outcomes

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

CARADERM is a French national multidisciplinary project which will prospectively enroll from 37 French centers any patient presenting with Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment or cutaneous adnexal carcinoma.

A structured and centralized database of clinical monitoring of patients will be established. Information captured will include clinical constitutional factors, factors linked to primary carcinoma, factors linked to lymph node involvement, "American Joint Committee on Cancer" (AJCC) stage at inclusion, recurrence patterns, therapeutic interventions (medical, surgical, radiotherapy and palliative strategies) with evaluation of response, date of death, date of latest news.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
9000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • France
      • Amiens, France
        • Recruiting
        • CHU Amiens Picardie
        • Contact:
          • Catherine Lok, MD
      • Angers, France
        • Recruiting
        • CHU Angers
        • Contact:
          • Ludovic Martin, MD
      • Annecy, France
        • Recruiting
        • CH Annecy Gennevois
        • Contact:
          • Julie De Quatrebarbes, MD
      • Besançon, France
        • Recruiting
        • CHU Besançon
        • Contact:
          • François Aubin, MD
      • Bobigny, France
        • Recruiting
        • CHU Avicenne
        • Contact:
          • Eve Maubec, MD
      • Boulogne-Billancourt, France
        • Recruiting
        • CHU Ambroise Pare
        • Contact:
          • Philippe Saiag, MD
      • Brest, France
        • Recruiting
        • Chu de Brest
        • Contact:
          • Laurent Misery, MD
      • Caen, France
        • Recruiting
        • CHU de CAEN
        • Contact:
          • Laurence VERNEUIL, MD, PhD
        • Principal Investigator:
          • Laurence VERNEUIL, MD, PhD
      • Clermont-Ferrand, France
        • Recruiting
        • Chu de Clermont Ferrand
        • Contact:
          • Michel d'Incan, MD
      • Grenoble, France
        • Recruiting
        • CHU de Grenoble
        • Contact:
          • Marie-Therese Leccia, MD
      • Limoges, France
        • Recruiting
        • CHU de Limoges
        • Contact:
          • Christophe Bedane, MD
      • Lyon, France
        • Recruiting
        • Centre Leon Berard
        • Contact:
          • Patrick Combemasle, MD
      • Marseille, France
        • Recruiting
        • Hôpital La Timone
        • Contact:
          • Jean Jacques Grob, MD
      • Montpellier, France
        • Recruiting
        • Hôpital St Eloi
        • Contact:
          • Bernard Guillot, MD
      • Nancy, France
        • Recruiting
        • CHU de Nancy
        • Contact:
          • Florence Granel-Brocard, MD
      • Nantes, France
        • Recruiting
        • CHU Nantes - Place Alexis Ricordeau
        • Principal Investigator:
          • Brigitte DRENO, MD, PhD
        • Contact:
          • Brigitte DRENO, MD, PhD
      • Nice, France
        • Recruiting
        • CHU de Nice
        • Contact:
          • Jean Philippe Lacour, MD
      • Orléans, France
        • Recruiting
        • CHR d'Orléans
        • Contact:
          • Guido Bens, MD
      • Paris, France
        • Recruiting
        • CHU Cochin
        • Contact:
          • Selim Aractingi, MD
      • Paris, France
        • Recruiting
        • CHU Bichat
        • Contact:
          • Vincent Descamps, MD
      • Paris, France
        • Recruiting
        • CHU St Louis
        • Contact:
          • Celeste Lebbe, MD
      • Pessac, France
        • Recruiting
        • CHU de Bordeaux
        • Contact:
          • Marie BEYLOT-BARRY, MD, PhD
        • Principal Investigator:
          • Marie BEYLOT-BARRY, MD, PhD
      • Pointe à Pitre, France
        • Recruiting
        • CHU de Pointe à Pitre
        • Contact:
          • Nadège Cordel, MD
      • Poitiers, France
        • Recruiting
        • CHU de Poitiers
        • Contact:
          • Gerard Guillet, MD
      • Reims, France
        • Recruiting
        • CHU de reims
        • Contact:
          • Florent Grange, MD
      • Rennes, France
        • Recruiting
        • CHU de Rennes
        • Contact:
          • Alain Dupuy
      • Rouen, France
        • Recruiting
        • CHU de Rouen
        • Contact:
          • Pascal JOLY, MD, PhD
        • Principal Investigator:
          • Pascal JOLY, MD, PhD
      • Strasbourg, France
        • Recruiting
        • CHU de Strasbourg
        • Contact:
          • Dan Lipsker, MD
      • Toulouse, France
        • Recruiting
        • CHU de Toulouse - Larrey
        • Principal Investigator:
          • Nicolas MEYER, MD, PhD
        • Contact:
          • Nicolas MEYER, MD, PhD
      • Tours, France
        • Recruiting
        • CHU de TOURS
        • Contact:
          • Laurent Machet, MD
      • Villejuif, France
        • Recruiting
        • Institut Gustave Roussy
        • Principal Investigator:
          • Caroline ROBERT, MD, PhD
        • Contact:
          • Caroline ROBERT, MD, PhD
    • Dijon
      • Dijon, Dijon, France, 21079
    • Le Mans
      • Le Mans, Le Mans, France, 72037
        • Recruiting
        • CH Le Mans
        • Contact:
    • Pierre-benite
      • Pierre-Bénite, Pierre-benite, France, 69495
        • Recruiting
        • Centre Hospitalier Lyon Sud
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

Description

Inclusion Criteria:

  • Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

Exclusion Criteria:

  • Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma
  • Patients refusal

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Merkel cell carcinoma
Advanced basal cell carcinoma
Cutaneous adnexal carcinomas

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Incidence and natural history of the 3 types of rare skin cancers
Time Frame: 10 years
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University Hospital, Lille

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Laurent MORTIER, MD,PhD, University Hospital, Lille

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 24, 2015

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 4, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 4, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 7, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 22, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 20, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NI_2014_60

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Merkel Cell Carcinoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings